Hot Features
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain fo... Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.02 | 0.02 | 0.02 | 72000 | 0.02 | DE |
| 4 | -0.003 | -13.0434782609 | 0.023 | 0.023 | 0.018 | 131782 | 0.02031634 | DE |
| 12 | 0.004 | 25 | 0.016 | 0.024 | 0.013 | 437434 | 0.0173354 | DE |
| 26 | -0.004 | -16.6666666667 | 0.024 | 0.034 | 0.013 | 441024 | 0.02175937 | DE |
| 52 | 0.009 | 81.8181818182 | 0.011 | 0.034 | 0.007 | 413676 | 0.02161428 | DE |
| 156 | 0.01 | 100 | 0.01 | 0.034 | 0.005 | 572512 | 0.014374 | DE |
| 260 | 0.01 | 100 | 0.01 | 0.034 | 0.005 | 572512 | 0.014374 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.